anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
A method, computing system and computer program product are provided. A first entity system that stores sensitive information associated with different entities applies a hash function a portion of the sensitive information to produce hash values. Transaction information pertaining to transactions performed on entity systems are stored within a blockchain database accessible to the entity systems. The transaction information includes hash values corresponding to associated entities from the entity systems. The hash values of the first entity system are compared to the hash values from others of the entity systems to determine entity systems containing information pertaining to same entities. The sensitive information for an entity of the first entity system is exchanged with the determined entity systems containing information for that entity.
BACKGROUND: Sarcopenia and intrinsic capacity (IC) declines pose significant challenges to healthy aging, particularly in the rapidly growing octogenarian population. This study aimed to elucidate the relationship between sarcopenia and declines in IC across multiple cohorts of community-dwelling older adults.
METHODS: Data from four Taiwanese cohorts were analyzed. Sarcopenia was diagnosed based on the Asian Working Group for Sarcopenia (AWGS) 2019 criteria (algorithm 1: categorized as either having possible sarcopenia or not (robust); algorithm 2: categorized as robust, possible sarcopenia or sarcopenia). IC was operationalized using the World Health Organization's Integrated Care for Older People (ICOPE) framework (step 1 and step 2), encompassing six domains: locomotion, vitality, vision, hearing, cognition, and psychological well-being. Multivariable logistic regression models were adopted to assess the association between sarcopenia and IC decline.
RESULTS: Among 599 octogenarians (median age 82.2 years, 54.8% male), the prevalence of possible sarcopenia (algorithm 1) was 64.6%. When adopting algorithm 2, the prevalence of possible sarcopenia and sarcopenia was 46,2% and 32.1%, respectively. After adjusting for covariates, participants with possible sarcopenia or sarcopenia (algorithm 2) were more likely to exhibit declines in vitality (ICOPE Step 1: possible sarcopenia aOR 3.65, sarcopenia aOR 4.74; ICOPE Step 2: possible sarcopenia aOR 5.11, sarcopenia aOR 14.77) and cognition (ICOPE Step 1: possible sarcopenia aOR 2.40, sarcopenia aOR 2.12; ICOPE Step 2: possible sarcopenia aOR 2.02, sarcopenia aOR 2.51) compared to robust individuals.
CONCLUSIONS: This study underscores the robust association between sarcopenia and declines in vitality and cognition among octogenarians, highlighting the importance of sarcopenia screening and management in promoting healthy longevity in this vulnerable population.
This study will investigate the effect of a 12 week intervention with a portfolio of 7 food products and 7 comparator products for their effect on glycated hemoglobin, blood lipids, blood vessel function and metabolic parameters in persons with prediabetes. Prediabetes precedes the manifestation of type 2 diabetes and is therefore an appropriate target for dietary interventions. It is also associated with increased cardiovascular disease (CVD) risk because of the presence of abdominal obesity, elevated LDL-cholesterol and reduced vascular function. CVD risk will be assessed based on the profile of lipids and other factors in the blood as well using specialized equipment for non-invasive monitoring of blood vessel function.

If the foods prove beneficial for managing blood glucose levels, the publication of results in scientific journals and in lay documents will increase awareness and provide important information of the health benefits of these products for consumers, health professionals and the food industry. It will also help individuals who may be able to manage their illnesses in a healthful non-pharmaceutical nutritional approach and who may benefit from physician-prescribed nutritional counseling with a focus on foods known to improve certain disease biomarkers. At this time these approaches lack practicality and direct application to individuals who are interested in adopting a new dietary regime capable of disease prevention.
Psychiatric comorbidity can be accounted for by a latent general psychopathology factor (p factor), which quantifies the variance that is shared to varying degrees by every dimension of psychopathology. It is unclear whether the entire continuum of the p factor shares the same genetic origin. We investigated whether mild, moderate, and extreme elevations on the p factor shared the same genetic etiology by, first, examining the linearity of the association between p factors across siblings (N = 580,891 pairs). Second, we estimated the group heritability in a twin sample (N = 17,170 pairs), which involves testing whether the same genetic variants influence both extreme and normal variations in the p factor. In both samples, the p factor was based on 10 register-based psychiatric diagnoses. Results showed that the association between siblings' p factors appeared linear, even into the extreme range. Likewise, the twin group heritabilities ranged from 0.42 to 0.45 (95% CI: 0.33-0.57) depending on the thresholds defining the probands (2-3.33 SD beyond the mean; >2 SD beyond the mean; >4.33 SD beyond the mean; and >5.33 SD beyond the mean), and these estimates were highly similar to the estimated individual differences heritability (0.41, 95% CI: 0.39-0.43), indicating that scores above and below these thresholds shared a common genetic origin. Together, these results suggest that the entire continuum of the p factor shares the same genetic origin, with common genetic variants likely playing an important role. This implies, first, genetic risk factors for the aspect that is shared between all forms of psychopathology (i.e., genetic risk factors for the p factor) might be generalizable between population-based cohorts with a higher prevalence of milder cases, and clinical samples with a preponderance of more severe cases. Second, prioritizing low-cost genome-wide association studies capable of identifying common genetic variants, rather than expensive whole genome sequencing that can identify rare variants, may increase the efficiency when studying the genetic architecture of the p factor.
The invention discloses an antioxidant peptide, an eggshell membrane hydrolysate containing the antioxidant peptide and application thereof. The amino acid sequence of the antioxidant peptide is any one of the following: NDADYPWPH, DFGPGPM, FPMRT, KPLCPP, DKDGPFRL, CRPPSLGR. The antioxidant peptide has strong antioxidant activity, and has one or more of ABTS free radical scavenging activity, ORAC activity, DPPH free radical scavenging activity, total antioxidant activity TAA and cell antioxidant activity. Wherein NDADYPWPH has the highest ORAC activity and ABTS free radical scavenging activity, which are 8.64 times and 3.42 times of reduced glutathione respectively. NDADYPWPH and KPLCPP have high ABTS, ORAC and cell antioxidant activity. The antioxidant peptide is obtained by hydrolyzing, separating and purifying eggshell membrane, and screening peptide groups and bioinformatics, is a novel unreported antioxidant peptide, has the characteristics of small molecular weight, direct absorption by human bodies, targeting and regulation of cell antioxidant pathways, and can be widely applied to the fields of foods, medicines, health care products, cosmetics and the like.
The invention provides a formula against infertility. The formula has the functions of nourishing blood and benefiting yin as well as reinforcing kidney and generating sperm. The formula is mainly used for treating amenorrhea caused by blood insufficiency and kidney deficiency, i.e., the formula has excellent effects for treating the amenorrhea with symptoms such as sexual hypoactivity, genital atrophy, vaginal secretion reduction, shedding of pubes, mastatrophy and mastatrophy. The traditional Chinese medicine composition is prepared from the following more than ten raw medicine materials which are matched by weight: angelica, radix paeoniae alba, rhizoma ligustici wallichii, prepared rhizome of rehmannia, rubus idaeus, dodder, fructus schisandrae, semen plantaginis, twotooth achyranthes root, medlar, curculigo and epimedium. The traditional Chinese medicine composition is mainly used for treating the amenorrhea caused by the blood insufficiency and the kidney deficiency of a female, i.e., the composition has the excellent effects for treating the amenorrhea with symptoms such as sexual hypoactivity, genital atrophy, vaginal secretion reduction, shedding of pubes, mastatrophy and mastatrophy. The formula provided by the invention is prepared by utilizing the purely natural traditional Chinese medicine ingredients, so that a side effect to a human body is avoided.
Although microbial pathogens utilize various strategies to evade plant immunity, host plants have evolved powerful defense mechanisms that can be activated in preparation for threat by infective organisms. Here, we identified one 24 kDa alkyl hydroperoxide reductase C (AhpC) from the culture supernatant of Ralstonia solanacearum strain FQY-4 (denoted RsAhpC) in the presence of host roots. RsAhpC contributes to H2O2 detoxification and the pathogenicity of R. solanacearum. However, the introduction of RsAhpC into the apoplast could activate immune defense, leading to suppression of pathogen colonization in both Nicotiana benthamiana and the Honghua Dajinyuan (HD) cultivar of N. tabacum. Consequently, overexpression of RsAhpC in the HD cultivar enhanced the resistance of tobacco to bacterial wilt disease caused by FQY-4. Overall, this study provides insight into the arms race between pathogens and their plant hosts. Specifically, it is firstly reported that plants can sense pathogen-derived AhpC to activate defenses, in addition to the role of AhpC in pathogen ROS detoxification. Therefore, the macromolecule AhpC produced by Ralstonia solanacearum has the ability to enhance plant defense as an elicitor, which provides a practical strategy for disease resistance breeding.
Systems and methods for detecting and classifying clinical features in medical images are disclosed. Natural language processes are applied to speech received from a dictation system to determine clinical and anatomical information for a medical image being viewed. In some examples, gaze location information identifying an eye position is received, as well as an image position for the medical image being viewed. Features of the medical image are detected and classified based on machine learning models. Anatomical associations are generated based on one or more of the classifications, the anatomical information, the gaze information, and the image position. The machine learning models can be trained based on the anatomical associations. In some examples, reports are generated based on the anatomical associations.
PROBLEM TO BE SOLVED: To obtain the subject inhibitor containing activated carbon as an active ingredient, inhibiting the expression of transforming growth factor-β, metalloprotease tissue inhibitor and collagen and useful for treating and preventing diseases exhibiting the disease states of extracellular matrix formation sthenia and fiberization sthenia. SOLUTION: This inhibitor contains activated carbon, preferably spherical activated carbon, as an active ingredient. The spherical activated carbon preferably has a diameter of 0.1-1 mm, a specific surface area of 700-1,500 m<2> /g, a fine pore radius of 100-75,000 Å and a porosity of 0.05-0.8 ml/g. The spherical activated carbon includes granulated spherical activated carbon obtained from carbonaceous powder, spherical activated carbon obtained by calcining an organic polymer and spherical activated carbon originating from a petroleum- based hydrocarbon (petroleum-based pitch). The inhibitor is preferably orally administered. The inhibitor is administered at a daily dose of 0.2-20 g (as the amount of the spherical activated carbon) with one or several portions for a human adult.
OBJECTIVE: Target depth, defined by the z-coordinate in the dorsoventral axis relative to the anterior commissure-posterior commissure axial plane of the MR-guided focused ultrasound (MRgFUS) lesion, is considered to be critical for tremor improvement and the occurrence of side effects such as gait impairment. However, although different z-coordinates are used in the literature, there are no comparative studies available with information on optimal lesion placement. This study aimed to compare two different MRgFUS lesion targets (z = +2 mm vs z = 0 mm) regarding efficacy and safety outcomes.
METHODS: The authors conducted a retrospective analysis of 52 patients with pharmacoresistant tremor disorders who received unilateral MRgFUS thalamotomy in the ventral intermediate nucleus for the first time between 2017 and 2022 by one neurosurgeon, with two different z-coordinates, either z = +2 mm (+2-mm group; n = 17) or z = 0 mm (0-mm group; n = 35), but otherwise identical parameters. Standardized video-recorded assessments of efficacy (including the Washington Heights-Inwood Genetic Study of Essential Tremor scale) and safety (using a standardized grading system) outcomes at baseline and at 6 months posttreatment were reviewed and compared. Moreover, overall patient satisfaction was extracted as documented by the examiner at 6 months.
RESULTS: Based on a multiple logistic regression analysis, the authors found that a more dorsal target with a z-coordinate of +2 mm as compared with 0 mm was associated with a higher incidence of any persistent side effect at 6 months (p = 0.02). Most consistently, sensory disturbances, although mild and nondisturbing in most cases, occurred more frequently in the +2-mm group (35% vs 11%, p = 0.007), while no significant differences were found for gait impairment (29% vs 35%) and arm ataxia (24% vs 11%). On the other hand, average tremor suppression was similar (63.6% vs 60.2%) between the groups. Here, higher efficacy was associated with a higher side effect burden in the 0-mm group but not in the +2-mm group. Despite the occurrence of side effects, general patient satisfaction was high (87% would undergo MRgFUS again) as most patients valued tremor suppression more.
CONCLUSIONS: A more ventral MRgFUS target of z = 0 mm seems to be associated with a more favorable safety and a comparable efficacy profile as compared with a more dorsal target of z = +2 mm, but prospective studies are warranted.
Subjects will be studied from 6 pm to 7 am. Subjects will have exercised at 7 am on that day.
Participants received 3 doses of talimogene laherparepvec administered by direct injection 3 weeks apart. At the discretion of the investigator, treatment with talimogene laherparepvec could continue beyond the third dose until week 15 in a regimen of at least 3 weeks between doses.
Patients who already received the ToggleLoc 2.9 mm soft tissue device in the shoulder. No additional surgery will be performed.
To provide a cosmetic laminated material that is capable of strongly adhering to a part of a living body, and can be easily peeled from the living body at any timing.SOLUTION: A cosmetic laminated material 100 comprises a cosmetic layer 101 which adheres to a part of a living body 1, and a cover coat layer 102. The cosmetic layer 101 and the cover coat layer 102 are arranged such that the cosmetic layer 101 is positioned between the living body 1 and the cover coat layer 102. The cosmetic layer 101 includes a resin composition for cosmetic containing a stimulation-responsive material causing a volume change by external stimulation, and adheres to a part of the living body 1 by a solidified matter of the resin composition for cosmetic. The contact angle of water on a surface of the solidified matter of the resin composition for cosmetic is 30° or more and 110° or less. The cosmetic layer 101 reduces bond strength to a part of the living body 1 by a volume change of the solidified matter caused by imparting external stimulation to the solidified matter of the resin composition for cosmetic. The cover coat layer 102 has the porosity of 40% or less.SELECTED DRAWING: Figure 1
A method can include receiving, from a user device of a user, a request for a remote diagnostic test session. A method can include initiate the remote diagnostic test session, the remote diagnostic test session comprising a video conference session. A method can include receive monitored video frame data from the user device, the monitored video frame data comprising video of the user performing a step of a remote diagnostic test procedure. A method can include detect in the monitored video frame data a diagnostic test tool. A method can include determine a bounding box including at least a portion of the diagnostic test tool. A method can include track a movement of the diagnostic test tool. A method can include determine an insertion depth of the diagnostic test tool. A method can include determine completion of a test action by the user.
A validation system and method are provided that examine data for use in tracking and/or generating an action plan. Data is received and stored at an implementation data store from production data sources. Evaluation rules are applied to the data by a data storage system. The evaluation rules are applied by running previously created scripts of commands of the data storage system. Applying the evaluation rules to the one or more sets of the data outputs a deviation measure for at least one of the sets of the data. The deviation measure and a restricted list of defined validation decisions is presented to an analyst for the data. A selected validation decision is received, and the data is validated for use in the action plan, rejected for use in the action plan, or identified as requiring additional analysis before being validated for use in the action plan.
The investigators have trained exercise trainers in Pain neuroscience and they will lead a set of classes, adapted to the needs of people with chronic pain. Focus groups with people with chronic pain detailed the important factors to consider in planning an exercise intervention, these being that the activity should be enjoyable, non-competitive and accessible to all levels of physical activity, and the venues should offer easy access with public transport. The investigators have identified three exercise types from the current LSP offerings that could meet the needs of people with chronic MSK pain, namely Tai Chi, Activator Pole walking and Aquarobics, which will run once a week for 8 weeks. The intervention group will also receive a paper-based education manual about physical activity and pain management education designed for people with chronic pain.
The invention belongs to the technical field of traditional Chinese medicines (TCMs) and provides a medicine used for treating urticaria, aiming to solve the problem of treating urticaria. The medicine is prepared from radix rehmanniae, Sichuan lovage rhizome, Chinese angelica, radix paeoniae alba, fineleaf schizonepeta herb, divaricate saposhnikovia root, white mulberry root-bark, Chinese wolfberry root-bark, polished round-grained rice, cortex dictamni, cicada slough, baical skullcap root, amur corktree bark, weeping forsythia capsule, gypsum and folium artemisiae argyi according to a certain proportion. A preparation method of the medicine is characterized by comprising the following steps: after mixing the medicines, adding 600ml of water to a first dose to decoct the first dose until 200ml and adding 500ml of water to a second dose to decoct the second dose until 200ml. The medicine is taken on an empty stomach respectively in the morning and in the evening each day. In the TCM preparation, radix rehmanniae, Sichuan lovage rhizome, Chinese angelica and radix paeoniae alba have the function of regulating ying and wei; fineleaf schizonepeta herb, divaricate saposhnikovia root and folium artemisiae argyi have the functions of dispelling wind and eliminating evil; white mulberry root-bark, Chinese wolfberry root-bark, polished round-grained rice, cortex dictamni, cicada slough, baical skullcap root, amur corktree bark, weeping forsythia capsule and gypsum have the functions of purging the lung, clearing heat and relieving itching. Through compatibility and synergy of the medicines, the medicine has good curative effects on urticaria.
The safety and efficacy of tacrolimus-based immunosuppression following orthotopic liver transplantation were assessed in two prospective, randomized, non-blinded multicenter trials. The active control groups were treated with a cyclosporine-based immunosuppressive regimen (CsA/AZA). Both trials used concomitant adrenal corticosteroids as part of the immunosuppressive regimens. These trials compared patient and graft survival rates at 12 months following transplantation.

In one trial, 529 patients were enrolled at 12 clinical sites in the United States; prior to surgery, 263 were randomized to the tacrolimus-based immunosuppressive regimen and 266 to the CsA/AZA. In 10 of the 12 sites, the same CsA/AZA protocol was used, while 2 sites used different control protocols. This trial excluded patients with renal dysfunction, fulminant hepatic failure with Stage IV encephalopathy, and cancers; pediatric patients (≤12 years old) were allowed.

In the second trial, 545 patients were enrolled at 8 clinical sites in Europe; prior to surgery, 270 were randomized to the tacrolimus-based immunosuppressive regimen and 275 to CsA/AZA. In this trial, each center used its local standard CsA/AZA protocol in the active-control arm. This trial excluded pediatric patients, but did allow enrollment of subjects with renal dysfunction, fulminant hepatic failure in Stage IV encephalopathy, and cancers other than primary hepatic with metastases.

One-year patient survival and graft survival in the tacrolimus-based treatment groups were similar to those in the CsA/AZA treatment groups in both trials. The overall 1-year patient survival (CsA/AZA and tacrolimus-based treatment groups combined) was 88% in the U.S. trial and 78% in the European trial. The overall 1-year graft survival (CsA/AZA and tacrolimus-based treatment groups combined) was 81% in the U.S. trial and 73% in the European trial. In both trials, the median time to convert from IV to oral tacrolimus dosing was 2 days.

Although there is a lack of direct correlation between tacrolimus concentrations and drug efficacy, data from clinical trials of liver transplant patients have shown an increasing incidence of adverse reactions with increasing trough blood concentrations. Most patients are stable when trough whole blood concentrations are maintained between 5 to 20 ng/mL. Long-term post-transplant patients are often maintained at the low end of this target range. 

Data from the U.S. clinical trial show that the median trough blood concentrations, measured at intervals from the second week to one year post-transplantation, ranged from 9.8 ng/mL to 19.4 ng/mL.

Additional pediatric use information is approved for Astellas Pharma US, Inc.’s Prograf (tacrolimus) products. However, due to Astellas Pharma US, Inc.’s marketing exclusivity rights, this drug product is not labeled with that information.